Discover the Advanced miniDxR Customizable
Lateral Flow Reader and Comprehensive CDMO and CRO Services at
Booth 30
CARLSBAD, Calif, Aug. 7, 2024 /PRNewswire/ -- DCN Dx, a
leading global provider of IVD CDMO and CRO services, announces its
participation in the NextGen Dx Summit 2024, held from August 19-21 at the Walter E. Washington
Convention Center in Washington,
DC. Attendees are invited to visit DCN Dx at booth 30 to
explore the company's latest innovations and comprehensive range of
services.
DCN Dx will have representatives from their assay development,
engineering, clinical research, and manufacturing teams on hand to
answer questions and discuss their comprehensive services. This
multidisciplinary approach ensures that DCN Dx can support every
stage of IVD product development, from concept through to
manufacturing, including IVD clinical trials and with particular
expertise in point-of-care testing.
Visit booth 30 for a demonstration of the miniDxR customizable
lateral flow reader. Designed by DCN Dx for point-of-care testing,
the miniDxR offers advanced imaging technology, superior
sensitivity and specificity, and robust cybersecurity features. It
is customizable for diverse diagnostic applications, providing
reliable and accurate results in diverse point-of-care
settings.
"We are looking forward to demonstrating the miniDxR at the
NextGen Dx Summit," said Pat
Vaughan, Ph.D., COO of DCN Dx. "From its advanced
capabilities to its range of customization options, our team
designed this reader with the specific needs of point-of-care
testing in mind."
"NextGen Dx provides an excellent platform to demonstrate how
our integrated CDMO and clinical research services can accelerate
the development and commercialization of innovative diagnostic
products," said Mitzi Rettinger,
Chief Revenue Officer of DCN Dx. "We are dedicated to partnering
with our clients to ensure the success of their IVD programs."
About DCN Dx
DCN Dx, based in Carlsbad,
California, is a global leader in IVD CDMO and CRO services.
Our multidisciplinary CDMO specializes in creating tailored assay
systems, consumables, and instruments for point-of-use
applications, with a particular expertise in lateral flow assays.
Our clinical research services group specializes in the planning,
execution, and oversight of IVD clinical trials, inclusive of
clinical operations, data management, and biostatistics.
Our personalized approach to IVD product development and
clinical trials has supported hundreds of programs and clients. We
can oversee every stage from concept to assay development and
platform integration, through clinical trials to manufacturing or
only handle the aspects you request. In addition to lateral flow
assays, our clinical research expertise extends to a wide range of
IVD devices, all with a focus on innovation, usability, and
performance.
With a commitment to quality, customer satisfaction, and
industry-leading expertise, DCN Dx is setting the benchmark for
excellence in IVD services. To learn more about how we can support
your diagnostic needs, visit dcndx.com.
For more information contact:
Mitzi Rettinger
Chief Revenue Officer, DCN Dx
Main: (760) 804-3886
Mobile: (512) 431-5836
381412@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dcn-dx-to-showcase-new-technologies-at-nextgen-dx-2024-302215647.html
SOURCE DCN Dx